JP2002527727A5 - - Google Patents

Download PDF

Info

Publication number
JP2002527727A5
JP2002527727A5 JP2000575892A JP2000575892A JP2002527727A5 JP 2002527727 A5 JP2002527727 A5 JP 2002527727A5 JP 2000575892 A JP2000575892 A JP 2000575892A JP 2000575892 A JP2000575892 A JP 2000575892A JP 2002527727 A5 JP2002527727 A5 JP 2002527727A5
Authority
JP
Japan
Prior art keywords
compound
receptor
pharmaceutical composition
identified
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000575892A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002527727A (ja
JP4685241B2 (ja
Filing date
Publication date
Priority claimed from US09/170,496 external-priority patent/US6555339B1/en
Application filed filed Critical
Publication of JP2002527727A publication Critical patent/JP2002527727A/ja
Publication of JP2002527727A5 publication Critical patent/JP2002527727A5/ja
Application granted granted Critical
Publication of JP4685241B2 publication Critical patent/JP4685241B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000575892A 1998-10-13 1999-10-12 疾患の処置に有用な細胞表面膜受容体のモジュレーターを同定する方法 Expired - Fee Related JP4685241B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/170,496 US6555339B1 (en) 1997-04-14 1998-10-13 Non-endogenous, constitutively activated human protein-coupled receptors
US09/170,496 1998-10-13
PCT/US1999/023935 WO2000021987A2 (en) 1998-10-13 1999-10-12 A method of identifying modulators of cell surface membrane receptors useful in the treatment of disease

Publications (3)

Publication Number Publication Date
JP2002527727A JP2002527727A (ja) 2002-08-27
JP2002527727A5 true JP2002527727A5 (enExample) 2006-11-30
JP4685241B2 JP4685241B2 (ja) 2011-05-18

Family

ID=22620080

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000575892A Expired - Fee Related JP4685241B2 (ja) 1998-10-13 1999-10-12 疾患の処置に有用な細胞表面膜受容体のモジュレーターを同定する方法
JP2000576019A Expired - Fee Related JP4672866B2 (ja) 1998-10-13 1999-10-12 非内因性の構成的に活性化されたヒトｇタンパク質共役受容体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2000576019A Expired - Fee Related JP4672866B2 (ja) 1998-10-13 1999-10-12 非内因性の構成的に活性化されたヒトｇタンパク質共役受容体

Country Status (14)

Country Link
US (2) US6555339B1 (enExample)
EP (1) EP1121431B9 (enExample)
JP (2) JP4685241B2 (enExample)
KR (1) KR100598752B1 (enExample)
CN (1) CN1329511C (enExample)
AT (1) ATE318311T1 (enExample)
AU (5) AU769987B2 (enExample)
CA (1) CA2342314A1 (enExample)
DE (3) DE69929993T4 (enExample)
DK (1) DK1121431T5 (enExample)
ES (1) ES2163384T3 (enExample)
IL (2) IL141965A0 (enExample)
NZ (1) NZ510331A (enExample)
WO (2) WO2000021987A2 (enExample)

Families Citing this family (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US6555339B1 (en) * 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
USRE42190E1 (en) 1998-11-20 2011-03-01 Arena Pharmaceuticals, Inc. Method of identifying a compound for inhibiting or stimulating human G protein-coupled receptors
US20030017528A1 (en) 1998-11-20 2003-01-23 Ruoping Chen Human orphan G protein-coupled receptors
US7816492B2 (en) * 1998-11-20 2010-10-19 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors
CA2645717A1 (en) * 1998-11-20 2000-06-02 Arena Pharmaceuticals, Inc. Human orphan g protein-coupled receptors
GB9903767D0 (en) * 1999-02-18 1999-04-14 Univ Glasgow Receptor assay
AU6385200A (en) * 1999-07-30 2001-02-19 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for prognostication, diagnosis, prevention, and treatment of bone-related disorders and other disorders
JP4768946B2 (ja) * 1999-11-17 2011-09-07 アリーナ ファーマシューティカルズ， インコーポレイテッド ヒトｇタンパク質共役型受容体の内因性および非内因性型
EP1240199A2 (en) * 1999-12-10 2002-09-18 AstraZeneca AB Method for screening of appetite control agents
EP1265922A2 (en) * 1999-12-17 2002-12-18 AstraZeneca AB Agonists and antagonists of the receptor gpr19 and their use in appetite control
GB0003898D0 (en) * 2000-02-18 2000-04-05 Glaxo Group Ltd Assay
EP1255779A2 (en) * 2000-02-18 2002-11-13 Glaxo Group Limited Identification of modulators of gpr41 or gpr42 activity
GB0003902D0 (en) * 2000-02-18 2000-04-05 Glaxo Group Ltd Assay
WO2001064872A2 (en) * 2000-02-29 2001-09-07 Millennium Pharmaceuticals, Inc. Gene 2465: methods and compositions for the diagnosis and treatment of cardiovascular, hepatic and bone disease
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
EP1149907A1 (en) * 2000-04-26 2001-10-31 Aventis Pharma Deutschland GmbH EDG8 receptor, its preparation and use
CA2406725C (en) * 2000-04-26 2013-01-15 Aventis Pharma Deutschland Gmbh Edg8 receptor, its preparation and use
JP2003531637A (ja) * 2000-05-03 2003-10-28 アストラゼネカ アクチボラグ 方 法
WO2001096567A1 (fr) * 2000-06-15 2001-12-20 Takeda Chemical Industries, Ltd. Nouvelle proteine receptrice couplee a la proteine g et adn de ce recepteur
CA2409776A1 (en) * 2000-06-16 2001-12-27 Incyte Genomics, Inc. G-protein coupled receptors
EP1293567B1 (en) 2000-06-21 2009-07-29 Takeda Pharmaceutical Company Limited Ligand to gpr8 and dna thereof
AU2001267898A1 (en) * 2000-07-04 2002-01-14 Takeda Chemical Industries Ltd. Novel g protein-coupled receptor protein and dna thereof
JP2004505648A (ja) * 2000-08-18 2004-02-26 ノバルティス　アクチエンゲゼルシャフト 炎症関連ｇタンパク質共役受容体
US7462457B2 (en) * 2000-08-30 2008-12-09 Johns Hopkins University School Of Medicine Identification of activated receptors and ion channels
WO2001027632A2 (en) * 2000-10-02 2001-04-19 Biofocus Discovery Limited Cellular receptor mutations predicted by multiple-sequence-allignment
AU2002218495A1 (en) * 2000-11-30 2002-06-11 Takeda Chemical Industries Ltd. Novel g protein-coupled receptor proteins and dnas thereof
US7241579B2 (en) 2000-12-22 2007-07-10 Smithkline Beecham Corporation Method of screening for GPR40 ligands
GB0031527D0 (en) * 2000-12-22 2001-02-07 Smithkline Beecham Plc New use
CN1516706A (zh) * 2001-02-26 2004-07-28 阿伦纳药品公司 人g蛋白偶联受体的内源性和非内源性形式
US6809104B2 (en) 2001-05-04 2004-10-26 Tularik Inc. Fused heterocyclic compounds
US6919176B2 (en) * 2001-05-07 2005-07-19 Amgen Inc. Polypeptides and nucleic acids associated with cancer
EP1394543B1 (en) 2001-05-15 2007-08-29 Takeda Pharmaceutical Company Limited Screening method
US20020177190A1 (en) * 2001-05-24 2002-11-28 Yanbin Liang Recombinant simian GPR3 receptor
AU2002310326A1 (en) * 2001-06-05 2002-12-23 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated versions of plant g protein-coupled receptor: gcr1
JP2003018992A (ja) * 2001-06-28 2003-01-21 Inst Of Physical & Chemical Res Ｐａｅｌ受容体、Ｐａｅｌ受容体発現細胞および動物、ならびにパーキンソン病治療薬のスクリーニング法
WO2003006504A2 (en) * 2001-07-13 2003-01-23 Akzo Nobel N.V. Allelic variants of gpr50
US20030109044A1 (en) * 2001-10-16 2003-06-12 Millennium Pharmaceuticals, Inc. Methods of using 279, a human G protein-coupled protein receptor
WO2003039341A2 (en) * 2001-11-05 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions to treat cardiovascular disease using 139, 258, 1261, 1486, 2398, 2414, 7660, 8587, 10183, 10550, 12680, 17921, 32248, 60489 or 93804
US6902902B2 (en) 2001-11-27 2005-06-07 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
CA2471504C (en) 2002-01-07 2014-05-20 Euroscreen S.A. Ligand for g-protein coupled receptor gpr43 and uses thereof
EP1336655A1 (en) * 2002-01-12 2003-08-20 Aventis Pharma Deutschland GmbH Method of identifying protein CAMS (constitutively active mutants)
AU2003210644A1 (en) * 2002-01-23 2003-09-02 Arena Pharmaceuticals, Inc. Non-endogenous versions of human g protein-coupled receptor: fshr
AU2003218638A1 (en) * 2002-02-06 2003-09-02 Bayer Aktiengesellschaft Diagnostics and therapeutics for diseases associated with neuromedin u1 receptor (nmu1)
WO2003068959A1 (fr) 2002-02-14 2003-08-21 Takeda Chemical Industries, Ltd. Nouveau procede de criblage
AU2003218234A1 (en) * 2002-03-15 2003-09-29 Arena Pharmaceuticals, Inc. Methods of expressing non-endogenous g protein coupled receptors in cells
WO2003104381A2 (en) * 2002-06-08 2003-12-18 Astrazeneca Ab Methods
JP2005534319A (ja) * 2002-08-01 2005-11-17 アリーナ ファーマシューティカルズ， インコーポレイテッド 虚血性心疾患および鬱血性心不全の処置のためのヒトｇタンパク質共役レセプターおよびそのモジュレーター
AU2003251471A1 (en) * 2002-08-06 2004-02-25 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human cxc chemokine receptor 5(cxcr5)
AU2003250165A1 (en) * 2002-08-06 2004-02-25 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 19 (gpr19)
EP1537879A4 (en) * 2002-08-22 2007-08-15 Kyowa Hakko Kogyo Kk MEANS FOR THE PREVENTION AND / OR TREATMENT OF ASTHMA
AU2003276106A1 (en) * 2002-10-24 2004-05-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 12 (gpr12)
US7056685B1 (en) * 2002-11-05 2006-06-06 Amgen Inc. Receptor ligands and methods of modulating receptors
MXPA05004739A (es) 2002-11-06 2005-08-02 Tularik Inc Compuestos heterociclicos fusionados.
CA2505322A1 (en) 2002-11-08 2004-05-21 Takeda Pharmaceutical Company Limited Receptor function regulator
US7189524B1 (en) 2002-11-25 2007-03-13 Amgen, Inc. Receptor ligands and methods of modulating receptors
WO2004050853A2 (en) * 2002-12-04 2004-06-17 Synaptic Pharmaceutical Corporation Uses of the snorf55 receptor
US20040157253A1 (en) * 2003-02-07 2004-08-12 Millennium Pharmaceuticals, Inc. Methods and compositions for use of inflammatory proteins in the diagnosis and treatment of metabolic disorders
WO2004083388A2 (en) * 2003-03-14 2004-09-30 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
US7427487B2 (en) * 2003-03-18 2008-09-23 Arena Pharmaceuticals, Inc. Constitutively active CXCR3 G protein-coupled chemokine receptor and modulators thereof for the treatment of inflammatory disorders
JPWO2004093912A1 (ja) * 2003-04-23 2006-07-13 協和醗酵工業株式会社 好中球性炎症疾患の予防および／または治療剤
WO2004099419A2 (en) * 2003-04-30 2004-11-18 Arena Pharmaceuticals, Inc. Methods and compositions for identifying modulators of g protein-coupled receptors
MXPA05012546A (es) * 2003-05-20 2006-05-25 Univ Glasgow Materiales y metodos que se relacionan con los oligomeros receptores acoplados a la proteina g.
EP1666880B1 (en) * 2003-09-11 2008-08-20 Takeda Pharmaceutical Company Limited Screening method
US20070276024A1 (en) * 2003-10-09 2007-11-29 Inverseon , Inc. Methods for Treating Diseases and Conditions with Inverse Agonists and for Screening for Agents Acting as Inverse Agonists
WO2005034871A2 (en) * 2003-10-09 2005-04-21 Inverseon, Inc. Methods for treating diseases and conditions with inverse agonists
WO2005040829A2 (en) * 2003-10-21 2005-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 17 (gpr17)
WO2005040211A2 (en) * 2003-10-23 2005-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 1 (gpr1)
WO2005040828A2 (en) * 2003-10-24 2005-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 49 (gpr49)
WO2005040825A2 (en) * 2003-10-24 2005-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 20 (gpr20)
CN104998273A (zh) 2003-11-06 2015-10-28 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
JP2007525491A (ja) * 2004-01-29 2007-09-06 セルゾーム・アクチェンゲゼルシャフト Ｇｐｒ４９の使用による、神経変性疾患の治療
CA2556757C (en) 2004-02-20 2011-05-03 Aventis Pharmaceuticals Inc. Oxydecahydronaphthalene modulators of hm74
WO2005101005A1 (en) * 2004-04-15 2005-10-27 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 32 (gpr32)
DE602005024537D1 (de) * 2004-04-27 2010-12-16 Takeda Pharmaceutical Neuer ligand eines g-protein-konjugierten rezeptorproteins und verwendung davon
CA2567520A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Maytansinoid-antibody conjugates
EP3088004B1 (en) 2004-09-23 2018-03-28 Genentech, Inc. Cysteine engineered antibodies and conjugates
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
US7528175B2 (en) * 2004-10-08 2009-05-05 Inverseon, Inc. Method of treating airway diseases with beta-adrenergic inverse agonists
GB0508988D0 (en) * 2005-05-03 2005-06-08 Novartis Ag Organic compounds
US8429755B2 (en) 2005-05-26 2013-04-23 Sandisk Technologies Inc. System and method for receiving digital content
US8673848B2 (en) 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
EP1934346A1 (en) * 2005-10-14 2008-06-25 Arena Pharmaceuticals, Inc. Gpr22 and methods relating thereto
JP2009519007A (ja) 2005-11-10 2009-05-14 アリーナ ファーマシューティカルズ， インコーポレイテッド 肥満およびそれに関連した状態を処置するためのヒトｇタンパク質共役受容体およびその調節因子
EP2121919B1 (en) * 2007-03-22 2012-02-08 Heptares Therapeutics Limited Mutant g-protein coupled receptors and methods for selecting them
GB0724051D0 (en) 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
GB0724860D0 (en) 2007-12-20 2008-01-30 Heptares Therapeutics Ltd Screening
GB0802474D0 (en) 2008-02-11 2008-03-19 Heptares Therapeutics Ltd Mutant proteins and methods for selecting them
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
WO2010091692A2 (en) * 2009-04-30 2010-08-19 H. Lundbeck A/S Constitutively active mutants and uses thereof
GB0910725D0 (en) 2009-06-22 2009-08-05 Heptares Therapeutics Ltd Mutant proteins and methods for producing them
CA2809819A1 (en) 2009-09-09 2011-03-17 Centrose, Llc Extracellular targeted drug conjugates
HRP20130953T1 (hr) 2010-04-15 2013-11-22 Spirogen Sàrl Pirolobenzodiazepini i njihovi konjugati
CA2799540A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
JP5804341B2 (ja) * 2010-08-06 2015-11-04 国立大学法人山口大学 エストロゲン関連疾患の判定方法
EP2640727B1 (en) 2010-11-17 2015-05-13 Genentech, Inc. Alaninyl maytansinol antibody conjugates
MX2013013054A (es) 2011-05-12 2014-02-20 Genentech Inc Metodo de monitoreo de lc-ms/ms de reaccion multiple para detectar anticuerpos terapeuticos en muestras de animales utilizando peptidos de firma de estructura.
PL2750713T3 (pl) 2011-10-14 2016-03-31 Medimmune Ltd Pirolobenzodiazepiny i ich koniugaty
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
MX364329B (es) 2012-10-12 2019-04-23 Medimmune Ltd Conjugados del anticuerpo pirrolobenzodiazepina.
DK2906253T3 (en) 2012-10-12 2018-10-22 Adc Therapeutics Sa Pyrrolobenzodiazepine anti-PSMA antibody conjugates
WO2014057120A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-antibody conjugates
DK2839860T3 (da) 2012-10-12 2019-06-17 Medimmune Ltd Pyrrolobenzodiazepiner og konjugater deraf
PL2906251T3 (pl) 2012-10-12 2018-02-28 Adc Therapeutics Sa Koniugaty pirolobenzodiazepina-przeciwciało anty-CD22
WO2014057119A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-antibody conjugates
ES2680153T3 (es) 2012-10-12 2018-09-04 Adc Therapeutics Sa Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
US8921307B2 (en) 2012-11-20 2014-12-30 Novartis Ag Synthetic linear apelin mimetics for the treatment of heart failure
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
CN105246894A (zh) 2012-12-21 2016-01-13 斯皮罗根有限公司 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
EA031585B1 (ru) 2012-12-21 2019-01-31 Медимьюн Лимитед Пирролобензодиазепины и их конъюгаты
ES2687439T3 (es) 2013-03-13 2018-10-25 Medimmune Limited Pirrolobenzodiazepinas y conjugados de las mismas
CN105142674B (zh) 2013-03-13 2018-11-13 麦迪穆有限责任公司 吡咯并苯并二氮杂卓和其结合物
NZ710745A (en) 2013-03-13 2019-03-29 Genentech Inc Pyrrolobenzodiazepines and conjugates thereof
EA201690278A1 (ru) 2013-07-25 2016-06-30 Новартис Аг Циклические полипептиды для лечения сердечной недостаточности
JP2016527249A (ja) 2013-07-25 2016-09-08 ノバルティス アーゲー 合成アペリンポリペプチドのバイオコンジュゲート
BR112016002829A2 (pt) 2013-08-12 2017-09-19 Genentech Inc Composto e processo para preparar o composto de conjugado anticorpo-¿droga, composição farmacêutica, método de tratamento do câncer, kit para o tratamento do câncer, intermediário ligante¿-droga, porção e composto de porção droga de dímero cbi
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
CN107106700B (zh) 2013-12-16 2020-10-30 基因泰克公司 肽模拟化合物及其抗体-药物缀合物
MX371092B (es) 2013-12-16 2020-01-16 Genentech Inc Compuestos peptidomimeticos y conjugados de anticuerpo-farmaco de los mismos.
JP6980384B2 (ja) 2013-12-16 2021-12-15 ジェネンテック， インコーポレイテッド １−（クロロメチル）−２，３−ジヒドロ−１ｈ−ベンゾ［ｅ］インドール二量体抗体−薬物コンジュゲート化合物、並びに使用及び処置の方法
CA2945706C (en) 2014-04-25 2023-10-24 Libramen Naturals Inc. G-protein coupled receptor 22 transformed cell lines and uses therefor
CN106687141A (zh) 2014-09-10 2017-05-17 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其缀合物
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
EP3388449A3 (en) 2014-09-12 2018-10-24 F. Hoffmann-La Roche AG Cysteine engineered antibodies and conjugates
JP6622293B2 (ja) 2014-09-12 2019-12-18 ジェネンテック， インコーポレイテッド アントラサイクリンジスルフィド中間体、抗体−薬物複合体、及び方法
KR20170067771A (ko) 2014-09-17 2017-06-16 제넨테크, 인크. 피롤로벤조디아제핀 및 이의 항체 디설파이드 컨주게이트
CN107148285B (zh) 2014-11-25 2022-01-04 Adc治疗股份有限公司 吡咯并苯并二氮杂䓬-抗体缀合物
AU2015358532C1 (en) 2014-12-03 2020-10-29 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
EP3416641A1 (en) 2016-02-16 2018-12-26 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Modulators of ccr9 for treating tumor resistance to immune responses
US20200164068A1 (en) 2016-02-16 2020-05-28 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Modulators of tumor immune resistance for the treatment of cancer
CN108700598A (zh) 2016-03-25 2018-10-23 豪夫迈·罗氏有限公司 多路总抗体和抗体缀合的药物量化测定法
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN109152843A (zh) 2016-05-20 2019-01-04 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
CN109313200B (zh) 2016-05-27 2022-10-04 豪夫迈·罗氏有限公司 用于表征位点特异性抗体-药物缀合物的生物分析性方法
US10639378B2 (en) 2016-06-06 2020-05-05 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
CN109689111B (zh) 2016-08-11 2024-04-05 基因泰克公司 吡咯并苯并二氮杂䓬前药及其抗体缀合物
EP3522933B1 (en) 2016-10-05 2021-12-15 F. Hoffmann-La Roche AG Methods for preparing antibody drug conjugates
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
BR112019016373B1 (pt) 2017-02-08 2022-01-25 Medimmune Limited Conjugado anticorpo-fármaco que se liga ao axl, composição e composição farmacêutica que compreende o mesmo e uso terapêutico do dito conjugado
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
ES2926144T3 (es) 2017-04-18 2022-10-24 Medimmune Ltd Conjugados de pirrolobenzodiazepina
JP7408396B2 (ja) 2017-04-20 2024-01-05 アーデーセー セラピューティクス ソシエテ アノニム 併用療法
PL3638373T3 (pl) 2017-06-14 2025-04-14 Adc Therapeutics Sa Schematy dawkowania dla podawania ADC anty-CD19
EP3668874B1 (en) 2017-08-18 2021-12-22 Medimmune Limited Pyrrolobenzodiazepine conjugates
US10301319B2 (en) 2017-09-20 2019-05-28 Ph Pharma Co., Ltd. Thailanstatin analogs
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
IL296050B2 (en) 2018-08-01 2024-12-01 Immunitybio Inc A quadricistronic system comprising a homing receptor or a cytokine, and chimeric antigen receptor for genetic modification of immunotherapies
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
CN113056287A (zh) 2018-10-24 2021-06-29 豪夫迈·罗氏有限公司 缀合的化学降解诱导剂及使用方法
JP2022513198A (ja) 2018-12-10 2022-02-07 ジェネンテック， インコーポレイテッド Ｆｃ含有タンパク質への部位特異的コンジュゲーションのための光架橋性ペプチド
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
MX2021010477A (es) 2019-03-15 2021-10-01 Medimmune Ltd Dimeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento de cancer.
US11230699B2 (en) 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
JP2024541058A (ja) 2021-11-03 2024-11-06 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． 抗体の特異的共役
CN114848822A (zh) * 2022-06-01 2022-08-05 合肥工业大学 Gpr31抑制剂在制备预防和治疗血管钙化药物中的应用
WO2024044659A1 (en) * 2022-08-24 2024-02-29 Tectonic Therapeutic, Inc. Constitutively active g protein-coupled receptor compositions and methods of use thereof
TW202432187A (zh) 2022-12-23 2024-08-16 美商建南德克公司 小腦蛋白降解劑結合物及其用途
WO2024220546A2 (en) 2023-04-17 2024-10-24 Peak Bio, Inc. Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates
WO2025207642A1 (en) * 2024-03-25 2025-10-02 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Cxcr3 isoforms to improve recombinant receptor trafficking

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3949711B2 (ja) 1990-02-26 2007-07-25 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 昆虫ステロイドレセプターｄｎａ配列の同定及び発現
CA2120518C (en) 1991-10-01 1998-10-13 Monika Konig A method of identifying ligands and antagonists of ligands
EP0745121B1 (en) * 1992-05-14 2007-06-20 Baylor College Of Medicine Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy
CA2145182C (en) 1992-09-25 2001-09-18 Jonathan A. Bard Dna encoding human alpha 1 adrenergic receptors and uses thereof
EP0612845A3 (en) 1993-02-26 1994-09-21 American Cyanamid Co Purified opioid receptor.
AU1173995A (en) 1993-11-10 1995-05-29 Arch Development Corporation Ubiquitous nuclear receptor: compositions and methods
EP0743520A3 (en) * 1993-12-30 1999-11-10 The Salk Institute For Biological Studies Novel uses for GAL4-receptor constructs
US5573944A (en) 1994-07-22 1996-11-12 President And Fellows Of Harvard College Yeast cell expressing heterologous receptor kinase
WO1996005302A1 (en) 1994-08-11 1996-02-22 Takeda Chemical Industries, Ltd. G protein coupled receptor protein, production, and use thereof
CA2135253A1 (en) 1994-11-07 1996-05-08 Michael Dennis Compound screening based on a window of chemical-messenger-independent activity
AU714642B2 (en) * 1995-06-06 2000-01-06 Human Genome Sciences, Inc. G-protein receptor HTNAD29
EP0862614A1 (en) 1995-09-20 1998-09-09 Molecular Geriatrics Corporation Yeast receptor and g-protein fusion protein
FR2742033B1 (fr) * 1995-12-08 1998-01-16 Achart Jacques Appareil pour l'ouverture de coquillages de mollusques bivalves
CA2239293A1 (en) 1995-12-11 1997-06-19 New England Medical Center Hosptials, Inc. Assay for and uses of peptide hormone receptor ligands
US5750353A (en) 1995-12-11 1998-05-12 New England Medical Center Hospitals, Inc. Assay for non-peptide agonists to peptide hormone receptors
US5932779A (en) * 1996-06-10 1999-08-03 Millennium Pharmaceuticals, Inc. Screening methods for compounds useful in the regulation of body weight
US6399326B1 (en) 1996-07-02 2002-06-04 President And Fellows Of Harvard College Nucleic acids encoding neural/pancreatic receptor tyrosine phosphatase
WO1998013513A2 (en) * 1996-09-24 1998-04-02 Cadus Pharmaceutical Corporation Methods and compositions for identifying receptor effectors
JP2001508293A (ja) 1996-12-27 2001-06-26 メルク エンド カンパニー インコーポレーテッド マウスガラニンレセプターｇａｌｒ２及び該レセプターをコードするヌクレオチド
US6403305B1 (en) 1997-02-06 2002-06-11 Cornell Research Foundation, Inc. Methods of identifying peptide agonists or negative antagonists of a G protein coupled receptor
AU6343998A (en) 1997-02-27 1998-09-18 Christina C. Egan Constitutively activated serotonin receptors
US6555339B1 (en) * 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
DK0965041T3 (da) 1997-04-14 2009-05-25 Arena Pharm Inc Fremgangsmåde til identifikation af modulatorer af celleoverflade-membranreceptorer, som kan anvendes til behandling af sygdomme
US5891720A (en) 1997-04-17 1999-04-06 Millennium Pharmaceuticals, Inc. Isolated DNA encoding a novel human G-protein coupled receptor
EP0878542A3 (en) 1997-04-22 2000-04-19 Smithkline Beecham Corporation cDNA clone HMTMF81 that encodes a novel human 7-transmembrane receptor
JP2002508660A (ja) 1997-06-12 2002-03-19 スミスクライン ビーチャム コーポレーション Ｈｍ７４ａ受容体
US5955308A (en) 1997-06-18 1999-09-21 Smithkline Beecham Corporation cDNA clone HEAOD54 that encodes a human 7-transmembrane receptor
US6222029B1 (en) 1997-08-01 2001-04-24 Genset 5′ ESTs for secreted proteins expressed in brain
ATE362983T1 (de) 1997-11-11 2007-06-15 Ono Pharmaceutical Co Menschlicher lysophosphatidsäure rezeptor und dessen verwendung
SE9704836D0 (sv) 1997-12-22 1997-12-22 Astra Pharma Inc Novel receptor
ATE440865T1 (de) 1998-03-26 2009-09-15 Univ Leland Stanford Junior Neue g-protein-gekoppelte rezeptoren aus säugetieren mit extrazellulären leucin-reicher region
JP2003514763A (ja) 1998-04-14 2003-04-22 アリーナ・フアーマシユーチカルズ・インコーポレーテツド 非内在性の構成的に活性化されるヒトセロトニンレセプターおよびその小分子調節物質
CN1231762C (zh) * 1998-07-31 2005-12-14 阿瑞那制药公司 对候选化合物进行直接鉴定的方法
AU5449099A (en) 1998-09-03 2000-03-27 Asahi Kasei Kabushiki Kaisha Novel receptor protein and method for diagnosing inflammatory diseases by using the same
WO2000022131A2 (en) 1998-10-13 2000-04-20 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human g protein-coupled receptors
US20030229216A1 (en) * 1998-10-13 2003-12-11 Ruoping Chen Constitutively activated human G protein coupled receptors
EP1153932A1 (en) 1999-02-19 2001-11-14 Takeda Chemical Industries, Ltd. Novel g protein-coupled receptor protein and dna thereof
IL146151A0 (en) 1999-07-15 2002-07-25 Solvay Pharm Bv Human-g-protein receptor
EP1196572A1 (en) 1999-07-27 2002-04-17 Smithkline Beecham Plc Axor21, a g-protein coupled receptor
EP1203023A1 (en) 1999-08-17 2002-05-08 MERCK PATENT GmbH Pgpcr-3 polypeptides and dna sequences thereof
WO2001014577A1 (en) 1999-08-24 2001-03-01 Smithkline Beecham Corporation Molecular cloning of a galanin like 7tm receptor (axor40)
WO2001016159A1 (en) 1999-08-27 2001-03-08 Smithkline Beecham Corporation Gpcr, theant
GB9923889D0 (en) 1999-10-08 1999-12-08 Pfizer Ltd Novel polypeptide
GB9924951D0 (en) 1999-10-21 1999-12-22 Pfizer Ltd Novel polypeptide
CA2386509A1 (en) 1999-10-27 2001-05-03 Pharmacia & Upjohn Company G protein-coupled receptors expressed in human brain
NZ531722A (en) 1999-11-17 2006-06-30 Arena Pharm Inc Endogenous and non-endogenous versions of human G protein-coupled receptors

Similar Documents

Publication Publication Date Title
JP2002527727A5 (enExample)
WO2000066180A3 (en) Method for enhancing contrast produced by mri
PL372849A1 (en) Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
Bouhnik et al. Immunologic identification of both plasma and human renal inactive renin as prorenin
JP2005527470A5 (enExample)
JP2003501068A5 (enExample)
JP2003531565A5 (enExample)
JP2004000251A5 (enExample)
TR200502189T1 (tr) Kompozisyonlar ve farmakolojik etken maddelerin aktarımı için yöntemler.
NO20065861L (no) Metode for a stabilisere proteiner
DE69830492D1 (de) Antikörper als ARZNEIMITTEL GEGEN LYMPHOCYTISCHE TUMORE (AUSSCHLIESSLICH MYELOME)
ATE359771T1 (de) Pellets mit venlafaxin-hydrochlorid
Jean-Baptiste et al. In vitro cyclic AMP-mediated lipolytic activity of endorphins, enkephalins and naloxone
Nürnberg et al. Non-peptide G-protein activators as promising tools in cell biology and potential drug leads
EP1367121A3 (en) Process for immobilizing polypeptides via the carboxyl group of the C-terminus
CA2379696A1 (en) Inhibition of renal uptake of radiomolecules with a combination of lysine and arginine
North et al. Radioimmunoassays for individual rat neurophysins
CA2484013A1 (en) Methods of modulating mitochondrial nad-dependent deacetylase
Shimomura et al. Differential effects of resact analogs on sperm respiration rates and cyclic nucleotide concentrations
RU2003102629A (ru) Фармацевтический компонент на основе паратиреоидного гормона человека и содержащая его фармацевтическая композиция для интраназального применения
AU2957099A (en) Novel physiologically active peptides and utilization thereof
JP2005535635A5 (enExample)
WO2006034496B1 (en) Methods and materials for optimization of electronic transportation and hybridization reactions
ITMI20011445A0 (it) Analoghi della cortistantina capaci di legarsi selettivamente ai recettori dei secretagoghi dell'ormone della crescita
EE200200042A (et) Ravimkoostis ja meetod selle valmistamiseks